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Zoledronic acid (Zol) is the most potent inhibitor of bone resorption among the bisphosphonates and is
commonly used for inhibiting bone metastasis. However, it remains unclear whether Zol provides a
survival beneﬁt. Recent ﬁndings indicate that epidermal growth factor (EGF) signaling is an important
mediator of bone metastasis. Thus, we examined the combined effects of Zol and an EGF receptor-
tyrosine kinase inhibitor, geﬁtinib, on the proliferation and invasion of a bone-seeking clone and the
breast cancer cell line MDA-MB-231. Combined treatment with Zol and geﬁtinib synergistically
inhibited both invasion and cell proliferation of the bone-seeking clone, but not those of the MDA-
MB-231 cells. Two-dimensional difference gel electrophoresis and mass spectrometry demonstrated
that stathmin was down-regulated during these cooperative effects. Stathmin is a signal transduction
regulatory factor which plays an important role in cell division and malignant tumor development. Our
data suggest that stathmin may be a promising target molecule for blocking bone metastasis of breast
cancer.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Approximately 75% of patients with advanced breast cancer
develop bone metastasis [1]. Patients with such bone metastasis
suffer skeletal-related events (SREs) such as pathologic fracture,
bone pain, spinal cord compression, and hypercalcemia [2]. As
pathologic fracture is associated with a signiﬁcantly increased
risk of death, prevention of bone metastasis improves not only the
quality of life but also the survival rate of patients with advanced
breast cancer [3–5].
Zoledronic acid (Zol), which contains two nitrogen atoms
within an imidazole ring structure, is the most potent inhibitor
of bone metastasis-related osteolysis and effectively reduces the
incidence of SREs [2]. Zol inhibits the mevalonate pathway in
osteoclasts, thus inhibiting the synthesis of farnesyl pyropho-
sphate synthase and geranylgeranyl pyrophosphonate, which are
required for prenylation of signaling GTPases. Recent preclinical. This is an open access article un
Pathology, National Defense
59-8513, Japan.studies have suggested that Zol exerts speciﬁc anti-tumor effects
including inhibition of cancer cell proliferation and/or invasion
[6–8].
Bisphosphonates signiﬁcantly reduce or prevent SREs. The use
of Zol for patients with bone metastases is currently the gold
standard treatment [4]. However, it is still unclear whether Zol
contributes to a survival beneﬁt [9]. Niikura et al. recently
reported that Zol did not prolong progression-free survival or
overall survival of breast cancer patients with bone-only metas-
tasis [10]. We aimed to enhance the anti-tumor effects on bone
metastasis, epidermal growth factor receptor (EGFR)-tyrosin
kinase inhibitor, geﬁtinib was used with Zol treatment.
Epidermal growth factor (EGF) signaling is also an important
mediator of bone metastasis. The EGFR is overexpressed in a wide
variety of cancer types including 30% of breast cancers [11]. In
addition to direct stimulation to cancer cell proliferation, EGF
signaling has been implicated in the modulation of stromal cells
in the tumor microenvironment [12,13]. Bone metastasis of the
breast cancer clonal cell line MDA-MB-231, which overexpresses
EGFR but lacks a proliferative response to EGF, is markedly
suppressed by inhibition of EGFR-tyrosine kinase. In fact, signiﬁ-
cant relief of bone pain in breast cancer patients with bone
metastases has been observed in a clinical trial of the EGFR-
tyrosine kinase inhibitor geﬁtinib [14,15].der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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established by repeated sequential passages of metastatic cells
from bone in nude mice and also in vitro, and shown that it
metastasizes exclusively to bone, producing larger osteolytic
lesions than the MDA-MB-231 parental cells. In contrast, MDA-
MB-231 cells target other organs such as brain, ovary, liver, and
adrenal gland. The biological properties of this bone-seeking
clone were shown to differ from those of MDA-MB-231, the
former producing more parathyroid hormone-released protein
than the latter. Activation of insulin-like growth factor I occurred,
and anchorage-independent growth was not inhibited by trans-
forming growth factor b [16].
In the present study, we examined the combined effect of Zol
and geﬁtinib on both cellular proliferation and invasion of the
bone-seeking clone, in comparison with those of the parental
MDA-MB-231 cells. The key protein responsible for the coopera-
tive effects was identiﬁed by 2-dimensional ﬂuorescence differ-
ence gel electrophoresis (2-D DIGE) and mass spectrometry.2. Materials and methods
2.1. Cell cultures and drug treatment
The human breast cancer cell line MDA-MB-231 and its bone-
seeking clone were studied. The bone-seeking clone had been
established by repeated cardiac inoculation of the MDA-MB-231
parental cells into nude mice [16]. These cells were cultured in RPMI
1640 medium (Life Technologies Japan, Tokyo, Japan) supplemented
with 10% fetal bovine serum (GE Healthcare Japan, Hino, Japan) and
1% penicillin (GE Healthcare Japan) at 37 1C under 5% CO2.
Zol was provided by Novartis Pharma (Basel, Switzerland).
Geﬁtinib (Iressas) was purchased from Tocris Bioscience (St.
Louis, MO, USA). Zol powder was dissolved in 0.1 N NaOH, and
geﬁtinib powder was dissolved in dimethyl sulfoxide (DMSO).
Cells were treated with 10 mM Zol and/or 1 mM geﬁtinib for 24 h
or 72 h. The ﬁnal concentration of NaOH or DMSO was less than
0.01% in all experiments.
2.2. Proliferation assay
Effects of Zol or geﬁtinib on cell proliferation were determined
using the WST-8 assay (Dojindo, Kumamoto, Japan). This cell
counting assay is sensitive for the determination of cell viability
in cell proliferation assay. WST-8 is reduced by dehydrogenase
activities in cells to give a yellow color formazan dye. The amount
of formazan dye is directly proportional to the number of living
cells. Brief protocol is as follows. Cells were seeded at a concen-
tration of 1104 cells per well in triplicate in a 96-well plate
(Asahi Glass, Tokyo, Japan), and pre-incubated at 37 1C for 24 h to
allow cell attachment. At 72 h after drug treatment, 10 ml of WST-
8 solution was added to each well and incubated at 37 1C for 1 h.
The assay is based on the extracellular reduction of WST-8 to a
water-soluble formazan dye formed by NADH produced in mito-
chondria. The augmentation of enzyme activity leads to an
increase in the amount of formazan dye, which was quantiﬁed
using a microplate reader (BIOTEC, Tokyo, Japan) by measuring
the absorbance at 450–550 nm. The above procedure was
repeated at least three times.
2.3. Invasion assay
Invasion was estimated using a 24-well Boyden chamber (BD
BioCoatTM MatrigelTM Invasion Chamber, BD Biosciences, San Jose, CA,
USA) in accordance with the manufacturer’s recommendations. After
hydration of thematrigel inserts for 2 h, 5.0104 cells in 500 ml RPMImedium containing 10 mM Zol, 1 mM geﬁtinib, or Zol plus geﬁtinib
were added to the upper chambers. The lower chambers were ﬁlled
with 750 ml RPMI medium containing drugs at the same concentra-
tions as those in the upper chambers. After 24 h of incubation at
37 1C, non-invasive cells were removed from the membranes, and the
membranes were ﬁxed with methanol and stained with crystal violet.
Only cells that had penetrated the membranes were counted in 10
randomly chosen high-power ﬁelds (HPFs) (400), and the mean
number per HPF was adopted as the number of cells that had invaded
through the membrane. The above experiments were performed in
triplicate and repeated at least three times.
2.4. Protein extraction
The bone-seeking clone was cultured to 70% conﬂuency and
treated with each drug (Zol, geﬁtinib, or Zol plus geﬁtinib) for
24 h. The cells were then washed twice with ice-cold PBS,
followed by ﬁxation with 10% trichloroacetic acid, and scraped
off into a tube and centrifuged at 3000 rpm for 10 min. The cell
pellet was treated with lysis buffer (30 mM Tris, 2 M thiourea,
7 M urea, 4% CHAPS, dilute HCl, and dH2O), and the resulting cell
lysate was separated from debris by centrifugation and sonicated
for 1.5 min at 250 W (Bioruptor, COSMO BIO, Yokohama, Japan).
Protein concentration was measured with a 2-D Quant kit (GE
Healthcare, Milwaukee, WI, USA).
2.5. 2-D DIGE (two-dimensional ﬂuorescence difference gel
electrophoresis)
Proteins were labeled with ﬂuorescent cyanine dyes (GE
Healthcare) in accordance with the manufacturer’s instructions.
In brief, 50 mg of a pair of samples extracted from the bone-
seeking clone treated or untreated with an anti-cancer drug was
adjusted to pH 8.5 with 50 mM NaOH and labeled with 400 pmol
Cy3 or Cy5, while another pair of samples was labeled inversely
with Cy5 or Cy3. The ﬂuorescence labeling was performed on ice
in the dark for 30 min, and then quenched with 1 ml of 10 mM
lysine (Sigma–Aldrich, St. Louis, USA) for 10 min. Each prepara-
tion was treated with 2 sample buffer containing 7 M urea, 2 M
thiourea, 4% CHAPS,1% immobilized pH gradient (IPG)-buffer, pH
range 4–7, and 2% dithiothreitol (DTT), and the ﬁnal volume was
adjusted to 260 ml with rehydration buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 0.5% IPG-buffer, pH range 4–7, 0.2% DTT).
The proteins were applied to Immobiline DryStrips (pH 4–7,
13 cm) and focused on an Ettan IPGphor II (GE Healthcare).
Four focused IPG strips were equilibrated, and then loaded
onto 12.5% SDS-polyacrylamide gels (30% acrylamide, 1.5 M Tris–
HCl pH 8.8, 10% SDS, 10% APS, 10% TEMED) using low-ﬂuores-
cence glass plates on an Ettan DALT II system (GE Healthcare). All
electrophoresis procedures were performed in the dark. After
SDS-PAGE, a pair of gels were scanned with a Typhoon 9410
scanner (GE Healthcare) with appropriate excitation/emission
wavelengths speciﬁc for Cy3 (532/580 nm) and Cy5 (633/
670 nm) to generate protein spot maps. The above procedure
was repeated three times.
DeCyder 7.0 software (GE Healthcare) was used for 2-D DIGE
analysis in accordance with the manufacturer’s recommendation.
The DeCyder differential in-gel analysis (DIA) module was used
for pairwise comparisons of each sample. Differential protein
spots (9ratio942, Po0.05) that showed consistent alteration
were selected.
2.6. In-gel digestion and mass spectrometric analysis
Peptide mass ﬁngerprinting (PMF) was performed for mass
spectrometric analysis. To extract the differential protein spots,
Fig. 1. Dose–response effects of Zol on cell proliferation of the bone-seeking clone
and the MDA-MB-231 line. The cell counting WST-8 assay that is sensitive for the
determination of cell viability was used. After 72 h of incubation, the formazan
dye was quantiﬁed by absorbance at 450–550 nm. Each bar represents the
standard error of the mean value from three replicates. Marked inhibitory effect
was detected by the 10 mM Zol treatment.
Fig. 2. Dose–response effects of geﬁtinib on cell proliferation of the bone-seeking
clone and the MDA-MB-231 line. Cell viability was evaluated by the WST-8 assay.
After 72 h of incubation, the formazan dye was quantiﬁed by absorbance at
450–550 nm. Each bar represents the standard error of the mean value from three
replicates. Marked inhibitory effect was detected by the 1.0 mM geﬁtinib
treatment.
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above. The gel was then stained with Coomassie blue for 1 h, and
destained for 1 h in 10% acetic acid and 40% methanol. After washing
with distilled water overnight, each spot was excised from the gel
using a 1-ml pipet and kept in a PCR plate with water. In-gel digestion
was performed as described by Kondo et al. [17]. Brieﬂy, reduction
was done using 45mg DTT in 10mM ammonium bicarbonate (ABM)
and alkylation using 40mg iodoacetamide in 50mM ABM. After
addition of 50% methanol, the gel plugs were washed in an ultrasonic
water bath with ice for 10 min, then dehydrated with 50–100%
acetonitrile (ACN) and incubated in vacuo for 10 min. Each procedure
was performed 4–6 times. After drying for 1 h, the gel plugs were
digested overnight in 0.5% trypsin in 50 mM ABM. The trypsin
digests were recovered with 45% ACN and 0.1% triﬂuoroacetic acid
(TFA), and the gel plugs were subjected to speedvac at room temp
for 20 min. Finally, 15 ml of 0.1% TFA was added.
The trypsin digests were subjected to spiral mass spectrometry
(JMS-S3000 MALDI-spiral TOF-TOF, Japan Electron Optics Labora-
tory, Akishima, Japan) and a database search was done using the
Mascot search engine at http://www.matrix-science.com. Proteins
that scored greater than 62 were judged to be signiﬁcant (Po0.05).
2.7. Western blot analysis
We further validated the identiﬁcation of proteins using
Western blot analysis. Samples from MDA-MB-231 cells and the
derivative bone-seeking clone treated with 1 mM geﬁtinib and/or
100 mM Zol were extracted with cell lysis buffer (1 M Tris pH 7.5,
NP-40, 5 M-NaCl, 0.5 M EDTA pH 7.5–8.0, 2 mM Na3VO4, 100 mM
NaF, 10 mM NaP2O7). Fifty micrograms of each sample was
separated using 12% SDS-PAGE gels, and transferred to a mem-
brane using a Trans-Blots TurboTM Blotting System (Bio-Rad,
Hercules, CA USA). After blocking with 5% non-fat milk powder
in PBS overnight at 4 1C, the membranes were incubated with
mouse monoclonal antibody against stathmin diluted 1:500 (BD
Biosciences, San Jose, CA) or an anti-b-actin antibody (dilution
1:2000) (Sigma) for 1 h at room temperature. After washing with
PBS containing 0.1% Tween 20, the membranes were incubated
with the secondary antibody, anti-mouse IgG diluted at 1:2000
(GE Healthcare), for 30 min at room temperature and then
washed for 30 min 4 times. The bands were reacted with
chemiluminescence reagent (SuperSignals, Thermo, Rockford, IL,
USA) and visualized using a luminescence image analyzer (LAS-
3000, Fuji Film, Kanagawa, Japan). The level of protein expression
was evaluated using Multi Gauge ver. 3.0 (Fuji Film).
2.8. Statistical analysis
The signiﬁcance of differences between the mean values of
triplicate experiments in the proliferation and invasion assays was
calculated using one-way analysis of variance (ANOVA) test. Differ-
ences were considered to be statistically signiﬁcant at Po0.05.Fig. 3. Effects of Zol and/or geﬁtinib on cell proliferation of the bone-seeking clone
and the MDA-MB-231 line. Cells were treated with/without 10 mM Zol and/or
1.0 mM geﬁtinib (Gef). Zol treatment signiﬁcantly inhibited proliferation of both
the bone-seeking clone (*) and the MDA-MB-231 parental cells (**). An inhibitory
effect of Zol plus Gef was detected on the bone-seeking clone (P o0.01) (***), but
not on MDA-MB-231. Each bar represents the standard error of the mean value.3. Results
3.1. Cell proliferation
Dose–response studies of Zol and geﬁtinib for both cell lines
were shown in Figs. 1 and 2, respectively. Treatment with 10 mM
Zol signiﬁcantly reduced the absorbance of the bone-seeking
clone from 0.77 nm (without any treatment) to 0.28 nm (reduc-
tion rate: 64%; 0.77–0.28/0.77; Po0.001 indicated by *), and also
that of MDA-MB-231 from 0.61 nm (without any treatment) to
0.17 nm (reduction rate: 72%; Po0.001 indicated by **) (Fig. 3). In
the bone-seeking clone, combined treatment with 10 mM Zol and1 mM geﬁtinib reduced the absorbance by 50% to 0.14 nm, in
comparison with a reduction to 0.28 nm by treatment with Zol
alone (Po0.01 indicated by ***). In contrast, the reduction rate
M. Oda et al. / Journal of Bone Oncology 1 (2012) 40–46 43was 18% in MDA-MB-231, and no signiﬁcant cooperative effect of
geﬁtinib with Zol was detected.3.2. Invasion assay
The effects of Zol and/or geﬁtinib on invasion by the bone-
seeking clone and MDA-MB-231 are shown in Fig. 4. The median
number of cells that invaded through the membrane was sig-
niﬁcantly reduced by treatment with 10 mM Zol from 113.7Fig. 4. Effects of Zol and/or geﬁtinib on invasion of the bone-seeking clone and
MDA-MB-231. A Boyden chamber was used to determine invasive ability. Cells
were treated with/without 10 mM Zol and/or 1.0 mM Gef. After 24 h of incubation,
non-invasive cells were removed from the membranes, and the membranes were
stained with crystal violet. Only cells that had penetrated the membranes were
counted in 10 HPFs (400) per ﬁlter. The mean number of invaded cells per HPF
was adopted as the number of invaded cells. Zol treatment signiﬁcantly decreased
the number of invaded cells for both the bone-seeking clone (*) and MDA-MB-
231(**). When the bone-seeking clone was treated with Zol plus Gef, a marked
inhibitory effect on invasion was detected (P o0.01) (***). However, no inhibitory
effect was detected on MDA-MB-231 cells. Each bar represents the standard error
of the mean value.
Fig. 5. Changes in the proﬁle of spots detected by 2-D DIGE in the bone-seeking clone
with increased expression were visualized as green spots. Four spots were up-regula
expression level were visualized as yellow. (b) High-magniﬁcation view of the area cor
yellow spots numbered by A–C are shown. (c) The expression levels of these three sp
regulated (red spots) by combined treatment with Zol and Gef. Conversely, when the pr
spots were conﬁrmed to be visualized as green. (For interpretation of the references to c(without any treatment) to 35.0 (69%) for the bone-seeking clone
(Po0.001 indicated by *) and from 80.0 (without any treatment)
to 36.7 (54%) for MDA-MB-231cells (Po0.05 indicated by **).
Combined treatment with 10 mM Zol plus 1 mM geﬁtinib mark-
edly reduced the number of invading cells from 35.0 (treatment
with Zol alone) to 4.3 (88%) for the bone-seeking clone (Po0.01
indicated by ***), but no such signiﬁcant effect was detected for
MDA-MB-231 cells.
3.3. 2-D DIGE
2-D DIGE identiﬁed four spots whose expression levels were
signiﬁcantly changed by treatment with Zol (Fig. 5a). All four
spots were up-regulated more than 3-fold. Treatment with
1.0 mM geﬁtinib alone induced differential up-regulation of the
expression of one spot (indicated by the arrowhead in Fig. 5c and
d), but the other spots showed no signiﬁcant change in expression
though many spots were differentially expressed within 2-folds
up- or down-regulation.
When the bone-seeking clone was treated with both Zol and
geﬁtinib, these four spots were conﬁrmed to show a change in
protein level. Moreover, three new spots, numbered AC,
appeared and showed signiﬁcant down-regulation of their
expression (Fig. 5d). These three spots, whose expression levels
were not changed by treatment with either Zol or Gef alone
(Fig. 5b and c, respectively), were located within a pH range of
5–6 and had molecular masses of 17–20 kDa. They were then
subjected to identiﬁcation by mass spectrometry.
3.4. Mass spectrometric analysis
We focused on the three protein spots (Fig. 5b–d AC) whose
expression was signiﬁcantly down-regulated by combined treat-
ment with the two drugs. Fig. 6 shows the peak ﬂow of the
digested peptide derived from spot C, which was identiﬁed as
stathmin by a Mascot search. Among the three spots, B and C
shared a common sequence of 16 peptides (P¼0.005). There was
no evident difference in the amino acid sequences that could. (a) When the protein lysate after treatment with Zol was labeled with cy3, spots
ted more than 3-fold. The majority of merged spots that showed no change in
responding to pH 5–6, 17–20 kDa, indicated by the blue rectangle in Fig. 5a. Three
ots were not changed by treatment with Gef. (d) These three spots were down-
oteins after treatment with both drugs were labeled with cy5, the down-regulated
olour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Peptide map derived from spots B and C and amino acid sequence determined by mass spectrometry. Each spot was excised from the gel, and in-gel digestion was
performed. The trypsin digests were subjected to spiral mass spectrometry, and a database search was performed using the Mascot software. Each peak of matched
peptides indicated by arrow head is appended by mass-to-charge ratio and amino acid sequence. Spots B and C showed almost the same sequence and were identiﬁed as
stathmin.
Fig. 7. Expression of stathmin determined by Western blot analysis. Samples with
equal amounts (50 mg) of cell lysates from the bone-seeking clone and MDA-MB-
231 were separated by 12% SDS-PAGE, transferred to membranes, and incubated
with the anti-stathmin monoclonal antibody. b-Actin was used as a positive
control. (a) Stathmin was expressed in the bone-seeking clone at a higher level
than in MDA-MB-231. (b) Stathmin was down-regulated by combined treatment
with Zol and Gef in the bone-seeking clone in comparison with Zol
treatment alone.
M. Oda et al. / Journal of Bone Oncology 1 (2012) 40–4644explain their different electrophoretic mobilities. Spot A could not
be identiﬁed in this study.3.5. Western blot analysis
Expression of stathmin in the bone-seeking clone was
increased 6-fold in comparison with that in the parental line,
MDA-MB-231 (Fig. 7a). In the bone-seeking clone, it was con-
ﬁrmed that the expression level of stathmin was halved by
combined treatment with Zol and geﬁtinib, in comparison with
Zol alone (Fig. 7b). This kind of down-regulation was not clearly
detected in MDA-MB-231 because MDA-MB-231 expressed stath-
min lower than bone-seeking clone without the treatment of Zol
or geﬁtinib. (data not shown).4. Discussion
Zol acts against osteolytic bone metastasis by inducing isopreny-
lation of proteins that are required for osteoclast survival. It also
induces apoptosis in several types of cancers, including primary
breast cancer, through the pathway responsible for prenylation of
small GTP-binding proteins [18]. It is well known that EGF is an anti-
apoptotic factor, and it is conceivable that geﬁtinib might enhance
the susceptibility of cancer cells to apoptosis. In fact, a combination
of Zol and geﬁtinib with SC-234 was reported to elicit a cooperative
anti-tumor effect in a non-bone metastatic model of breast and
prostate cancer [19]. Such combined treatment has also been
reported to elicit a tumor-suppressive effect, which is signiﬁcantly
more effective and less toxic in vitro and in vivo, on EGFR-mutated
non-small cell lung carcinoma cells, in comparison with the indivi-
dual anti-tumor effect of geﬁtinib or Zol alone [20]. In the present
study using a bone-seeking breast cancer clonal cell line in vitro, we
demonstrated an enhanced inhibitory effect on bone metastasis
using Zol plus geﬁtinib in combination.
The bone-seeking clone used in this study showed higher
expression of stathmin than the parental MDA-MB-231 cell line.
Similarly, using 2-D DIGE and mass spectrometry, Xu et al. have
demonstrated that stathmin-1 was up-regulated in a highly
metastatic variant of MDA-MB-231 [21]. A proteomic analysis
designed to examine the time course of neoplastic transformation
of human mammary epithelial cells showed that stathmin was
up-regulated in parallel with an early and progressive increase in
metastatic potential [22]. Moreover, overexpression of stathmin
has been detected in different types of human malignant tissue,
such as sarcoma [23], gastric cancer [24], endometrial cancer [25],
colon cancer [26], nasopharyngeal cancer [27], and breast cancer
[28,29]. All these data suggest that overexpression of stathmin is
signiﬁcantly correlated with clinically aggressive behavior such as
lymph node metastasis, poor histologic differentiation, an
advanced clinical stage, or poor prognosis.
In the present study, we found that stathmin was signiﬁcantly
down-regulated upon treatment with a combination of Zol and
geﬁtinib. The down-regulation of stathmin, which was not
detected by 2-D DIGE after treatment with either agent alone,
M. Oda et al. / Journal of Bone Oncology 1 (2012) 40–46 45was considered to be attributable to cooperative effect of Zol
and geﬁtinib. Down-regulation of endogenous stathmin by trans-
fection with an adenovirus expressing stathmin small interfering
RNA (siRNA) was reported to decrease the migration of
HT1080 (human ﬁbrosarcoma) cells through ﬁbronectin-coated
Transwells [23]. Silencing of stathmin by siRNA has also been
shown to decrease the proliferation, viability, or invasion of
cancer cells derived from malignancies of the prostate [30], breast
[31], stomach [24], and colon [26]. These ﬁndings are in
accord with our present data indicating that down-regulation of
stathmin paralleled the inhibition of both cell proliferation and
invasion of the bone-seeking clone upon combined treatment
with Zol and geﬁtinib, suggesting that stathmin could be a
potential candidate for therapeutic target for inhibition of bone
metastasis.
Finally, our data allow us to propose a potentially promising
strategy for cancer therapy. Down-regulation of stathmin has
been reported to enhance the sensitivity to anti-microtubule
drugs [32–34]. Because the combined treatment of Zol and
geﬁtinib down-regulates the expression of stathmin, a further
inhibitory effect against breast cancer might be expected if
anti-microtubule drugs were to be added. Although a preclinical
study would be needed to investigate this triple strategy,
synergistic anti-angiogenic effects of stathmin inhibition and
taxol exposure have already been reported [35]. Combination
of these three agents might be indicated for patients with
aggressive breast cancers such as those with the triple negative
phenotype.
In summary, we have demonstrated that combined treatment
with Zol and geﬁtinib, which down-regulate stathmin, produces
enhanced anti-tumor effects on bone homing breast cancer cells
in vitro. Thus, co-administration of Zol and geﬁtinib may con-
stitute a basis for developing a more effective therapy for patients
with bone metastasis.Acknowledgments
We are grateful to Mr. Masahiro Hashimoto and Mr. Yoshiyuki
Itoh, Japan Electron Optics Laboratory (JEOL) Co., Ltd., Akishima,
Tokyo, Japan, for providing the data of mass spectrometric
analysis, and Ms. Kozue Suzuki for skilled assistance with protein
labeling and loading for 2D-DIGE. This study was supported in
part by the Foundation for Promotion of Cancer Research, a
Ministry of Defense Grant (Osamu Matsubara and Keiichi Iwaya),
by a Grant-in-aid for Scientiﬁc Research (C) (KAKENHI24590457)
and by the National Cancer Center Research and Development
Fund (23-A-11).
References
[1] Coleman RE. Metastatic bone disease: clinical features, pathophysiology and
treatment strategies. Cancer Treatment Reviews 2001;27:165–76.
[2] Neville HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the
treatment and prevention of metastatic bone disease. European Journal of
Cancer 2010;46:1211–22.
[3] Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures
correlate with reduced survival in patients with malignant bone disease.
Cancer 2007;110:1860–7.
[4] Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Takashima S, et al.
Zoledronic acid signiﬁcantly reduces skeletal complications compared with
placebo in Japanese women with bone metastases from breast cancer: a
randomized, placebo-controlled trial. Journal of Clinical Oncology 2005;
23:3314–21.
[5] Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Major P, et al. Bone
markers and their prognostic value in metastatic bone disease:
clinical evidence and future directions. Cancer Treatment Reviews 2008;34:
629–39.
[6] Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Clezardin P,
et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, anearly event in the formation of bone metastases. Cancer Research 2000;
60:2949–54.
[7] Denoyelle C, Hong L, Vannier J-P, Soria J, Soria C. New insights into the actions
of bisphosphonate Zoledronic acid in breast cancer cells by dual RhoA-
dependent and -independent effects. British Journal of Cancer 2003;
88:1631–40.
[8] Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA.
Zoledronic acid directly suppresses cell proliferation and induces apoptosis in
highly tumorigenic prostate and breast cancers. Journal of Carcinogenesis
2011;10:1–10.
[9] Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Bell R, et al.
Breast-cancer adjuvant therapy with Zoledronic acid. New England Journal of
Medicine 2011;365:1396–405.
[10] Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Theriault RL. Retrospective
analysis of antitumor effects of Zoledronic acid in breast cancer patients with
bone-only metastases. Cancer 2011:1–9.
[11] Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of
EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor
geﬁtinib. Journal of Cellular Physiology 2011;226:2316–28.
[12] Lu X, Wang Q, Hu G, Poznak CV, Fleisher M, Kang Y, et al. ADAMTS1 and
MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling
cascade for bone metastasis. Genes & Development 2009;23:1882–94.
[13] Lu X, Kang Y. Epidermal growth factor signaling and bone metastasis. British
Journal of Cancer 2010;102:457–61.
[14] Albain K, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Pusztai L, et al.
Open-label, phase II, multicenter trial of ZD1839 (‘Iressa’) in patients with
advanced breast cancer. Breast Cancer Research and Treatment 2002;76:20
abstract.
[15] Von MG, Jonat W, Beckmann M, De BA, Kleeberg U, Schneeweiss A, et al. A
multicenter phase II trial to evaluate geﬁtinib (‘Iressa’, ZD1839)(500 mg/d) in
patients with metastatic breast cancer after previous chemotherapy treat-
ment. European Journal of Cancer 2003;1:S133 abstract.
[16] Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking
clone exhibits different biological properties from the MDA-MB-231 parental
human breast cancer cells and a brain-seeking clone in vivo and in vitro.
Journal of Bone and Mineral Research 2001;16:1486–95.
[17] Kondo T, Hirohashi S. Application of highly sensitive ﬂuorescent dyes (CyDye
DIGE Fluor saturation dyes) to laser microdissection and two-dimensional
difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nature
Protocols 2006;1:2940–50.
[18] Caraglia M, D’Alessandro AM, Marra M, Giuberti G, Vitale G, Abbruzzese A,
et al. The farnesyl transferase inhibitor R115777 (Zarnestras) synergistically
enhances growth inhibition and apoptosis induced on epidermoid cancer
cells by Zoledronic acid (Zometas) and pamidronate. Oncogene 2004;23:
6900–13.
[19] Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Tortora G, et al.
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and geﬁtinib in
inhibiting breast and prostate cancer. Endocrine-Related Cancer 2005;12:
1051–8.
[20] Chang JW, Hsieh JJ, Shen YC, Yeh KY, Wang CH, Hsu T, et al. Bisphosphonate
Zoledronic acid enhances the inhibitory effects of geﬁtinib on EGFR-mutated
non-small cell lung carcinoma cells. Cancer Letters 2009;278:17–26.
[21] Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic
variant of human breast cancer cells using two-dimensional differential gel
electrophoresis. Journal of Cancer Research and Clinical Oncology
2010;136:1545–56.
[22] DeAngelis JT, Li Y, Mitchell N, Wilson L, Kim H, Tollefsbol TO. 2D difference
gel electrophoresis analysis of different time points during the course of
neoplastic transformation of human mammary epithelial cells. Journal of
Proteome Research 2010;447:447–58.
[23] Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Baldassarre G,
et al. Stathmin activity inﬂuences sarcoma cell shape, motility, and meta-
static potential. Molecular Biology of the Cell 2008;19:2003–13.
[24] Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, Oh SO, et al. Overexpression of
stathmin 1 in the diffuse type of gastric cancer and its roles in proliferation
and migration of gastric cancer cells. British Journal of Cancer 2010;102:
710–8.
[25] Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Salvesen HB,
et al. Stathmin overexpression identiﬁes high-risk patients and lymph node
metastasis in endometrial cancer. Clinical Cancer Research 2011;17:
3368–77.
[26] Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, Zhao L, et al. Stathmin, a new target
of PRL-3 identiﬁed by proteomic methods, plays a key role in progression and
metastasis of colorectal cancer. Journal of Proteome Research 2010;9:
4897–905.
[27] Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Xiao ZQ. Identiﬁcation of
novel nasopharyngeal carcinoma biomarkers by laser capture microdissec-
tion and proteomic analysis. Clinical Cancer Research 2008;14:435–45.
[28] Brattsand G. Correlation of oncoprotein 18/stathmin expression in human
breast cancer with established prognostic factors. British Journal of Cancer
2000;83:311–8.
[29] Curmi PA, Nogues C, Lachkar S, Carelle N, Gonthier MP, Bieche I, et al.
Overexpression of stathmin in breast carcinomas points out to highly
proliferative tumours. British Journal of Cancer 2000;82:142–50.
[30] Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Molecular
Cancer Therapeutics 2005;4:1821–9.
M. Oda et al. / Journal of Bone Oncology 1 (2012) 40–4646[31] Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor
function in breast cancer cell lines harboring mutant p53. Oncogene
2007;26:1003–12.
[32] Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH, et al. Inhibiting proliferation
and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA
interference-mediated downregulation of stathmin expression. Molecular
Medicine 2007;13:567–75.
[33] Long M, Yin G, Liu L, Lin F, Wang X, Ren J, et al. Adenovirus-mediated Aurora
A shRNA driven by stathmin promoter suppressed tumor growth andenhanced paclitaxel chemotherapy sensitivity in human breast carcinoma
cells. Cancer Gene Therapy 2012;19:271–81.
[34] Alli E, Babula JB, Yang JM, Hait WN. Effect of stathmin on the sensitivity to
antimicrotubule drugs in human breast cancer. Cancer Research 2002;62:
6864–9.
[35] Mistry SJ, Bank A, Atweh GF. Synergistic antiangiogenic effects of
stathmin inhibition and taxol exposure. Molecular Cancer Research
2007;5:773–82.
